Investment Rating - The report assigns a "Buy" rating for the company with a target price of 13.07 HKD, based on a 20x PE for 2025 [5]. Core Insights - The company is positioned for accelerated growth through a dual strategy of "independent research and global expansion," which enhances its international transformation potential [1][12]. - In 2024, the company achieved a revenue of 10.784 billion RMB, a year-on-year increase of 10.59%, and a net profit of 2.286 billion RMB, up 31.28% year-on-year, driven by increased demand for core products in nuclear medicine and cardiovascular precision intervention [21]. Summary by Sections 1. Company Overview - Founded in 1939, the company operates across three main sectors: nuclear medicine for tumor diagnosis and treatment, cardiovascular precision intervention, and pharmaceutical technology [1][12]. - The company has over 10,000 employees globally and more than 30 subsidiaries, with a diverse product portfolio exceeding 200 items in the medical insurance directory [1][12]. 2. Pharmaceutical Technology - The company is focused on developing innovative drugs in respiratory and critical care, with STC3141 showing promise as a new treatment for sepsis [2][31]. - The global market for sepsis treatment is projected to grow from 12.54 billion USD in 2024 to 19.37 billion USD by 2032, indicating significant unmet clinical needs [40]. 3. Nuclear Medicine - The company has established a complete industrial chain in nuclear medicine, with its core product, Yttrium-90 microsphere injection, rapidly gaining market traction since its approval in 2022 [3][4]. - The company is advancing multiple nuclear medicine products through clinical trials, including TLX591 for prostate cancer and GPN02006 for liver cancer diagnosis, positioning itself in the global first-tier of development [4][12]. 4. Financial Forecast - Revenue projections for 2025-2027 are 12.405 billion RMB, 13.729 billion RMB, and 15.113 billion RMB, respectively, with net profits expected to be 2.121 billion RMB, 2.396 billion RMB, and 2.773 billion RMB [5].

Summary of the Conference Call for Yuan Da Pharmaceutical Company Overview - Yuan Da Pharmaceutical's core business includes three main segments: nuclear medicine for oncology and cardiovascular precision treatment, pharmaceutical technology, and biotechnology [2][5] - The company reported a revenue of HKD 11.6 billion last year, with a net profit of HKD 1.76 billion after excluding investment income, achieving a gross margin of nearly 60% and a net margin of approximately 20% [2][6] Key Points and Arguments Business Growth and Development - The E90 product has shown significant growth, contributing to the pharmaceutical technology segment's recovery post-collective procurement [2][3] - The STC3,141 product for sepsis has a domestic market potential of over HKD 10 billion and an overseas potential exceeding USD 10 billion, currently in Phase II clinical trials [2][8] - The company plans to launch multiple collaborative and self-developed products by 2030-2031, with four self-developed products already in clinical research [2][9] Financial Performance - The company maintained a double-digit revenue growth last year, with a projected similar performance for the current year [6] - The total dividend for 2024 is expected to be HKD 900 million, resulting in a dividend yield of 5% [6] Product Development - E90 is designed for treating unresectable colorectal cancer liver metastases and advanced primary liver cancer, with a focus on improving accessibility through insurance coverage [7] - The STC3,141 product is positioned as a major player in the sepsis market, with significant potential despite some uncertainties [8] Strategic Initiatives - The company is expanding its domestic production capacity to control costs and enhance its competitive edge in the synthetic drug sector [10][11] - In the pharmaceutical technology segment, the company has passed the peak of collective procurement and anticipates the launch of several ophthalmic and agricultural products in the coming years [12] Innovations in Specific Fields - In the field of otolaryngology, the company is focusing on traditional Chinese medicine and OTC innovative drugs, addressing unmet medical needs [14] - The cardiovascular emergency segment is adapting to the aging population, with new products mitigating the impact of collective procurement on short-term performance [15] - The biotechnology segment has a strong market presence with amino acids and taurine, planning to enhance high-value terminal products for future profit growth [16] Overall Market Position - The company’s overall market capitalization is estimated between HKD 55 billion to HKD 60 billion, with current market value below HKD 30 billion, indicating significant upside potential [3] Additional Important Insights - The company has a comprehensive layout in the synthetic drug field, with a first-class production base and international-level R&D platform [10] - The company is actively involved in clinical trials for sepsis and related conditions, with a focus on immune regulation [13] - The heart and brain vascular intervention segment is developing a range of innovative devices, with 27 products already in the pipeline [17] This summary encapsulates the key aspects of Yuan Da Pharmaceutical's conference call, highlighting its business segments, financial performance, product development, strategic initiatives, and overall market position.

Investment Rating - The industry investment rating is "stronger than the market" (预计6个月内，行业指数表现强于市场表现5%以上) [35] Core Viewpoints - The report emphasizes the importance of multi-party collaboration in supporting the development of innovative drugs and medical devices, highlighting the integration of data, policy, and funding as essential elements for growth [4] - The report notes that recent measures from the Financial Supervisory Administration and the Medical Insurance Bureau aim to promote the development of commercial health insurance, which will provide additional support for the innovation and development of drugs and medical devices [4] Summary by Sections Industry Insights - The Medical Insurance Bureau's recent meetings have established a comprehensive support system for innovative drugs and medical devices, involving various stakeholders such as research institutions, enterprises, medical institutions, financial companies, and government departments [4] - The Financial Supervisory Administration has released measures to enhance the quality of commercial health insurance, which will further support the biopharmaceutical industry's innovation [4] Investment Strategy - The report suggests focusing on innovative pharmaceutical companies with rich pipelines, such as 恒瑞医药 (Hengrui Medicine), 百济神州 (BeiGene), and 中国生物制药 (China Biologic Products) [6] - It also highlights companies with significant single-product potential and those leading in advanced technology platforms, recommending关注 (focus on) companies like 凯莱英 (Kailaiying) and 药明康德 (WuXi AppTec) [6] Market Performance - The pharmaceutical sector experienced a decline of 0.84% last week, ranking last among 28 industries, while the Shanghai and Shenzhen 300 Index rose by 1.23% [9][21] - The report indicates that the pharmaceutical sector's valuation is currently at 30.91 times (TTM), with a premium of 37.32% compared to the overall A-shares excluding financials [27]

截至13:33，恒生港股通创新药指数（HSSCID）跌1.29%，权重股中，晶泰控股涨8.2%，同源康医药-B 涨1.6%，康方生物涨1.4%，锦欣生殖涨0.3%，欧康维视生物-B涨0.3%，和黄医药跌0.4%，四环医药跌 0.7%，远大医药涨0.3%，康哲药业涨1.1%，石药集团跌0.5%。 今年前7个月，江苏获批上市的创新药达14个，已超去年全年的13个。全国共有49个创新药获批上市。 中金公司指出，看好创新药长期产业发展趋势。国内工程师红利、丰富临床资源和支持性政策多边加持 下，国产创新药已逐渐从跟随时代走向FIC/BIC创新。经历几年耕耘，国内品种商业化放量，并有望受 益于支付端政策改革，创新药企盈利能力提升；在研管线数据优异，大额BD持续达成。进入2.0时代的 创新药产业已经逐步完成质的提升。 相关产品： 易方达恒生港股通创新药联接A(024328) 易方达恒生港股通创新药联接C(024329) ...

截至2025年8月6日 10:32，中证香港创新药指数(931787)下跌1.33%。成分股方面涨跌互现，康希诺生物 (06185)领涨12.57%，晶泰控股(02228)上涨6.67%，远大医药(00512)上涨2.83%；君实生物(01877)领跌， 绿叶制药(02186)、三生制药(01530)跟跌。港股创新药ETF(513120)红盘蓄势。 流动性方面，港股创新药ETF盘中换手26.06%，成交43.40亿元，市场交投活跃。拉长时间看，截至8月 5日，港股创新药ETF近1周日均成交121.72亿元。 港股创新药ETF(513120)，（联接A:019670，联接C:019671）：紧密跟踪中证香港创新药指数，投资港 股创新药产业。值得注意的是，港股创新药ETF(513120)支持T+0交易，这意味着投资者可以在交易日 内进行多次买卖，极大地提高了资金的使用效率和流动性。 港股创新药ETF紧密跟踪中证香港创新药指数，根据申万二级行业分布，中证香港创新药指数生物制品 +化学制药权重占比达92.5%，这也是当下ETF跟踪的指数中，较为"纯血"的创新药行业指数之一。 数据显示，截至2025年7月31日，中证香 ...

隔夜美股三大指数集体收跌，中概指数跌0.56%。连续2日反弹的港股三大指数低开，恒指跌0.15%，国 指跌0.21%，恒生科技指数跌0.31%。盘面上，大型科技股多数呈现下跌行情，其中，百度跌超1%，阿 里巴巴、小米、美团、网易均飘绿，腾讯、京东小幅上涨；创新药概念股继续走强，与DoveTree完成总 订单规模约470亿港元的管线合作签约，晶泰科技大涨15%，歌礼制药、康方生物、远大医药、金斯瑞 生物科技皆上涨；宇树发布新款四足机器狗，机器人概念股多数活跃，纸业股继续昨日上涨。另一方 面，餐饮股走低，百胜中国跌超6%，钢铁股、汽车股、电信股、快递物流股普遍下跌。(格隆汇) 相关事件 港股收评：恒生指数涨0.62%！光伏、钢铁成亮点，军工、芯片股表现疲软 港股收评：恒生指数跌 0.56%！内房股、汽车股低迷，黄金股逆势爆发 港股收评：三大指数涨跌不一，恒生科技指数涨 0.56%，医药、军工、汽车大涨 港股收评：恒指再度失守24000，恒生科技指数跌0.33%，医药、芯片、 券商大涨居前 ...

【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com (责任编辑：宋政 HN002) 格隆汇8月6日｜隔夜美股三大指数集体收跌，中概指数跌0.56%。连续2日反弹的港股三大指数低开， 恒指跌0.15%，国指跌0.21%，恒生科技指数跌0.31%。盘面上，大型科技股多数呈现下跌行情，其中， 百度跌超1%，阿里巴巴、小米、美团、网易均飘绿，腾讯、京东小幅上涨；创新药概念股继续走强， 与DoveTree完成总订单规模约470亿港元的管线合作签约，晶泰科技大涨15%，歌礼制药、康方生物、 远大医药、金斯瑞生物科技皆上涨；宇树发布新款四足机器狗，机器人概念股多数活跃，纸业股继续昨 日上涨。另一方面，餐饮股走低，百胜中国跌超6%，钢铁股、汽车股、电信股、快递物流股普遍下 跌。(格隆汇) ...

格隆汇8月5日丨远大医药(00512.HK)宣布，公司将于2025年8月19日(星期二)举行董事会会议，藉以(其 中包括)考虑及批准公司及其附属公司截至2025年6月30日止六个月的中期业绩以及其他事项(如有)。 ...

承董事會命 遠大醫藥集團有限公司 主席 唐緯坤博士 香港，二零二五年八月五日 於本公告日期，董事會由四名執行董事唐緯坤博士、周超先生、楊光先生及林芷伊女士， 及四名獨立非執行董事蘇彩雲女士、邢麗娜博士、裴更博士及胡野碧先生組成。 * 僅供識別 ( 於百慕達註冊成立之有限公司 ) (股份代號: 00512) 董事會召開日期 遠大醫藥集團有限公司(「本公司」)之董事會(「董事會」)謹此宣佈，本公司將於 二零二五年八月十九日(星期二)舉行董事會會議，藉以(其中包括)考慮及批准本公司及 其附屬公司截至二零二五年六月三十日止六個月之中期業績以及其他事項(如有)。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示概不會就本公佈全部或任何部分內容而 產生或因依賴該等內容而引致之任何損失承擔任何責任。 Grand Pharmaceutical Group Limited 遠大醫藥集團有限公司* ...

远大医药集团有限公司是一家加科技创新型国际化医药企业，主要业务包括制药科技、核药抗肿瘤诊疗 及心脑血管精准介入诊疗科技，以及生物科技。该公司拥有全球超过一万名员工，30多家境内外附属公 司，5个技术平台和8个研发中心，超过200个医保目录产品和16个销售额超过一亿的产品，业务覆盖多 个医疗领域，近年来也在全球范围内布局创新药械产品，并与多家世界领先医药企业、大学和科研机构 建立合作关系。 8月5日，远大医药(00512)盘中下跌2.28%，截至15:46，报8.15元/股，成交3.0亿元。 截至2024年年报，远大医药营业总收入107.84亿元、净利润22.86亿元。 本文源自：金融界 作者：行情君 ...